Russell Investments Group Ltd. Has $1.26 Million Position in Esperion Therapeutics Inc (ESPR)

Russell Investments Group Ltd. boosted its holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) by 8.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,072 shares of the biopharmaceutical company’s stock after acquiring an additional 1,913 shares during the quarter. Russell Investments Group Ltd. owned 0.10% of Esperion Therapeutics worth $1,257,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Voya Investment Management LLC increased its position in shares of Esperion Therapeutics by 12.7% during the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after purchasing an additional 806 shares during the period. TIAA CREF Investment Management LLC boosted its stake in shares of Esperion Therapeutics by 3.0% during the 2nd quarter. TIAA CREF Investment Management LLC now owns 39,074 shares of the biopharmaceutical company’s stock worth $1,808,000 after buying an additional 1,148 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of Esperion Therapeutics by 5.3% during the 2nd quarter. Alliancebernstein L.P. now owns 30,070 shares of the biopharmaceutical company’s stock worth $1,392,000 after buying an additional 1,500 shares during the last quarter. Parametric Portfolio Associates LLC boosted its stake in shares of Esperion Therapeutics by 3.4% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 50,420 shares of the biopharmaceutical company’s stock worth $2,333,000 after buying an additional 1,658 shares during the last quarter. Finally, Rhumbline Advisers boosted its stake in shares of Esperion Therapeutics by 10.6% during the 3rd quarter. Rhumbline Advisers now owns 20,500 shares of the biopharmaceutical company’s stock worth $1,027,000 after buying an additional 1,960 shares during the last quarter. Hedge funds and other institutional investors own 92.24% of the company’s stock.

In other Esperion Therapeutics news, Director Nicole Vitullo sold 9,326 shares of the firm’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now owns 2,472 shares in the company, valued at $133,117.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 32.50% of the company’s stock.

Shares of Esperion Therapeutics Inc (NASDAQ ESPR) opened at $65.58 on Thursday. Esperion Therapeutics Inc has a 52-week low of $10.71 and a 52-week high of $66.62. The firm has a market cap of $1,660.00, a P/E ratio of -9.56 and a beta of 2.73.

Esperion Therapeutics (NASDAQ:ESPR) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter in the previous year, the business posted ($0.77) EPS. equities research analysts forecast that Esperion Therapeutics Inc will post -7.3 earnings per share for the current fiscal year.

ESPR has been the subject of a number of recent research reports. Northland Securities restated a “buy” rating and set a $72.00 price objective on shares of Esperion Therapeutics in a research note on Friday, November 10th. Stifel Nicolaus reaffirmed a “buy” rating and set a $70.00 target price on shares of Esperion Therapeutics in a report on Wednesday, October 4th. BidaskClub raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 16th. Chardan Capital lifted their price objective on shares of Esperion Therapeutics from $20.00 to $75.00 and gave the company a “neutral” rating in a research note on Wednesday, December 6th. Finally, Cowen initiated coverage on shares of Esperion Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price objective on the stock. Seven research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Esperion Therapeutics currently has an average rating of “Buy” and a consensus target price of $60.85.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/12/28/russell-investments-group-ltd-has-1-26-million-position-in-esperion-therapeutics-inc-espr.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

What are top analysts saying about Esperion Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit